NKTR — Nektar Therapeutics Balance Sheet
0.000.00%
- $1.15bn
- $882.75m
- $98.43m
Annual balance sheet for Nektar Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,062 | 734 | 505 | 304 | 255 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 38.9 | 22.5 | 5.98 | 1.21 | 0 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,138 | 796 | 546 | 331 | 261 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 186 | 178 | 85.9 | 36.9 | 11.8 |
| Net Goodwill | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,539 | 1,117 | 711 | 398 | 304 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 116 | 85.2 | 68.2 | 51.3 | 61.4 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 461 | 438 | 344 | 267 | 243 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 1,077 | 680 | 367 | 131 | 60.7 |
| Total Liabilities & Shareholders' Equity | 1,539 | 1,117 | 711 | 398 | 304 |
| Total Common Shares Outstanding |